^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PCSK9 inhibitor

    Related drugs:
    13h
    A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    metformin
    1d
    Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) (clinicaltrials.gov)
    P3, N=118, Completed, University of California, San Francisco | Recruiting --> Completed | Trial completion date: Aug 2026 --> Aug 2025
    Trial completion • Trial completion date
    |
    CD4 (CD4 Molecule) • CRP (C-reactive protein)
    |
    Praluent (alirocumab)
    1d
    A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease (clinicaltrials.gov)
    P1, N=85, Recruiting, Verve Therapeutics, Inc. | N=36 --> 85 | Trial completion date: Aug 2026 --> Aug 2027
    Enrollment change • Trial completion date
    2d
    AMUNDSEN: Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI (clinicaltrials.gov)
    P4, N=2166, Active, not recruiting, Assistance Publique - Hôpitaux de Paris | Recruiting --> Active, not recruiting | Trial completion date: Sep 2027 --> May 2028 | Trial primary completion date: Sep 2025 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • Real-world evidence
    |
    Repatha (evolocumab)
    6d
    A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. (clinicaltrials.gov)
    P4, N=402, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial primary completion date
    6d
    BE REAL: The Belgian REAL (BE.REAL) Registry (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Novartis Pharmaceuticals | N=300 --> 600 | Trial completion date: Jul 2026 --> Mar 2029 | Trial primary completion date: Jul 2026 --> Mar 2029
    Enrollment change • Trial completion date • Trial primary completion date
    6d
    A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia (clinicaltrials.gov)
    P2, N=214, Completed, Shenzhen Salubris Pharmaceuticals Co., Ltd.
    New P2 trial
    |
    atorvastatin
    8d
    ORION-4: A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (clinicaltrials.gov)
    P3, N=16124, Active, not recruiting, University of Oxford | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial primary completion date
    8d
    A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years (clinicaltrials.gov)
    P1, N=14, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    metformin
    9d
    Impact of PCSK9 inhibitor on T lymphocyte subsets and cytokines in patients with acute ischemic stroke: an exploratory analysis of a randomized clinical trial. (PubMed, Front Neurol)
    In this study, a total of 100 patients with AIS were included for the current analysis (n = 50 for combination therapy of evolocumab and atorvastatin, PI group, n = 50 for atorvastatin monotherapy, AT group). http://www.chictr.org.cn; Identifier: ChicTR2200059445. Date of registration: 29 April 2022.
    Clinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Repatha (evolocumab) • atorvastatin
    14d
    STREAMLINE: Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    ACS: Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes (clinicaltrials.gov)
    P3, N=300, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    APOB (Apolipoprotein B)